Recent developments include a public offering to raise up to $4 million, leadership appointments, expansion of service access in Asia-Pacific, and showcasing of the NAMkind platform at industry conferences.

• VivoSim Labs priced a best efforts public offering in April 2026 to raise up to $4 million, issuing common stock and warrants, with net proceeds of approximately $2.5 million after expenses [N1].
• Norman Staskey was appointed as Chief Financial Officer in early 2025 [N2].
• The company expanded Asia-Pacific access to its NAMkind toxicology services in January 2026, which positively impacted stock performance [N3].
• VivoSim Labs showcased its NAMkind platform's liver toxicology prediction capabilities at the Digestive Disease Week Conference in May 2025 [N4].
• The company emerged from stealth mode in April 2025, emphasizing its focus on non-animal toxicology models following an FDA initiative [N5].
• Organovo Holdings, Inc. changed its name to VivoSim Labs, Inc. and adopted the ticker symbol 'VIVS' in April 2025 [N6].
• The company completed the sale of its FXR program to Eli Lilly and Company in March 2025 [N8].
• Organovo issued a business update with quick facts in March 2025 [N7].

The company's NAMkind™ platform addresses a growing demand for non-animal toxicology testing driven by regulatory initiatives, potentially positioning VivoSim Labs as a key player in safer and more ethical drug discovery. Expansion into the Asia-Pacific market and successful capital raises support operational scaling. The divestiture of non-core assets like the FXR program to Eli Lilly may allow focus on core competencies and innovation.

VivoSim Labs faces risks typical of early-stage biotech firms, including sustained net losses and the need for ongoing capital to fund operations. The company's financials show significant net losses and negative earnings per share. Market acceptance of non-animal toxicology models and competition from established players could limit growth. Legal contingencies, while not quantified, add uncertainty. Stock price volatility following capital raises indicates market sensitivity to dilution and execution risks.

VivoSim Labs' moat is centered on its proprietary NAMkind™ platform, which offers industry-leading liver toxicology prediction capabilities using non-animal models. This technology aligns with regulatory trends favoring alternatives to animal testing, potentially providing a competitive advantage in drug discovery services. The company's early mover status in this niche and partnerships expanding geographic access contribute to its defensibility.

• Financial Losses and Capital Needs: The company reported a net loss of $13.84 million for fiscal year 2026 and negative EPS, indicating ongoing operating losses and the need for additional capital to sustain operations.
• Market and Regulatory Acceptance: The adoption of non-animal toxicology models depends on regulatory acceptance and market demand, which may evolve and impact the company's growth prospects.
• Legal Contingencies: VivoSim Labs is subject to various legal claims and contingencies arising in the ordinary course of business, with outcomes and potential liabilities uncertain.
• Stock Dilution and Volatility: Recent public offerings and warrant issuances may dilute existing shareholders and contribute to stock price volatility.

• VivoSim Labs, INC. is a company focused on drug discovery using non-animal toxicology models, leveraging its NAMkind™ platform for liver toxicology prediction.
• The company emerged from stealth mode in 2025 following an FDA initiative supporting non-animal toxicology models.
• VivoSim Labs was formerly known as Organovo Holdings, Inc., with the name change and new ticker symbol 'VIVS' announced in April 2025.
• The company completed the sale of its FXR program to Eli Lilly and Company in early 2025.
• VivoSim Labs appointed Norman Staskey as Chief Financial Officer in January 2025.
• In March-April 2026, VivoSim Labs priced a best efforts public offering to raise up to $4 million, issuing common stock, pre-funded warrants, and common warrants.
• The offering included two tranches, with the initial tranche closing on April 1, 2026, raising net proceeds of approximately $2.5 million after expenses.
• The company expanded Asia-Pacific access to its NAMkind toxicology services in early 2026.
• Financial figures from the 10-K filed July 14, 2026, show cash and equivalents of $5.02 million and current assets of $6.63 million as of March 31, 2026.
• The company reported a net loss of $13.84 million and basic and diluted EPS of -$5.35 for the fiscal year ending March 31, 2026.
• Liquidity ratios as of March 31, 2026, include a current ratio of 2.38 and a cash ratio of 5.38, indicating a strong liquidity position.
• The company may be subject to various legal claims and contingencies arising in the ordinary course of business, with no meaningful estimate of potential liabilities disclosed.